Chemomab Therapeutics Ltd. announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The new study reinforces the extensive evidence showing the potential of Chemomab?s CCL24-neutralizing antibody, CM-101, to interrupt the biological processes driving PSC disease progression and severity. The study, ?Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis?

has been published in the current online version of the peer-reviewed International Journal of Molecular Science. The study applied machine learning to proteomic profiles of PSC patient sera to assess the involvement of CCL24 and to identify markers of disease presence, severity and cirrhosis. The pathway analysis underscored the importance of both fibrosis-related pathways and pathways associated with immune response and inflammation in PSC.

Notably, the analysis showed that enrichment for PSC-related biological pathways was associated with high levels of CCL24 and that patients with cirrhosis had higher levels of CCL24, providing further evidence for the role of CCL24 in disease progression and severity. The authors also noted that the biomarkers identified in this study have significant translational importance, offering potential advancements in the monitoring of disease progression in clinical settings. A second study published in the online edition of the journal Drug Safety, Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies, summarized the findings of three Phase 1 studies of CM-101.

It concluded that CM-101 successfully neutralizes CCL24, a key factor linked to inflammatory and fibrotic diseases. Phase 1a studies of intravenous (IV) and subcutaneous (SC) administration of CM-101 in healthy participants demonstrated rare and mild adverse events. In Phase 1b studies in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), both IV and SC administered CM-101 exhibited good tolerability, with a notable reduction in serum levels of inflammatory, fibrotic and collagen turnover biomarkers, suggesting its therapeutic potential in addressing inflammatory and fibrotic conditions.